N4 Pharma PLC Covid-19 Project Update (8066J)
16 April 2020 - 8:00AM
UK Regulatory
TIDMN4P
RNS Number : 8066J
N4 Pharma PLC
16 April 2020
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014 ("MAR").
16 April 2020
N4 Pharma Plc
("N4 Pharma" or the "Company")
Covid-19 Project Update
Further to the Company's announcement on 25 March 2020, N4
Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to provide an update on the timing and
work that it will be undertaking as part of its Covid-19 proof of
concept research project for Nuvec (R) .
The Company has received delivery of the initial quantity of the
Covid-19 plasmid DNA from the National Institute for Health ("NIH")
in the USA and has appointed Evotec International Gmbh ("Evotec")
to undertake the Nuvec(R) proof of concept work for use with
Covid-19 at its site in Toulouse, France.
The initial proof of concept work will commence during the first
week of May once all required materials have been sourced by Evotec
and will involve the following three stages:
1. amplification of the plasmid DNA received from the NIH to
provide sufficient plasmid DNA to undertake the in vitro and
initial in vivo studies. This work is expected to take
approximately four weeks;
2. demonstrating whether Nuvec(R) is capable of loading the
Covid-19 plasmid and transfecting murine peripheral blood
mononuclear ("PBMC") cells in vitro, and induce an expression of
the spike protein in target cells. This stage is expected to last a
further ten weeks; and
3. subject to positive results being achieved at stage 2,
undertaking an initial pre in vivo study to demonstrate expression
of the spike protein in target cells in a murine target. This stage
would be expected to take a further ten weeks, commencing in
mid-July.
Once the stage 3 results have been reviewed, the Company will
then determine whether to do a further in vivo study to demonstrate
the capability of Nuvec(R) to generate Covid-19 specific
antibodies. In light of the current global urgency around
treatments for Covid-19, the Company would also seek to
collaborate, where it can, with appropriate partners to accelerate
further studies at this juncture.
Covid-19 Virtual Partnering Event
The Company is pleased to announce that it has registered as a
participant in the Covid-19 Virtual Partnering event organised
jointly by Lyonbiopole, Evaluate Ltd. and Inova and being held
between 20 April and 6 May. The aim of the event is to foster
connections and accelerate global collaboration to coordinate the
industry's response to the Covid-19 pandemic. Further details on
the event are available at www.virtual-partnering.com.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"The initial proof of concept data package for Nuvec(R) using
Covid-19 is expected to last approximately six months and is a key
priority for the Company to demonstrate the versatility and
potential for our Nuvec(R) delivery system, and to license Nuvec(R)
to partners looking to develop vaccines for this virus.
"As announced previously, we are not doing this work to develop
a vaccine for Coronavirus but rather to demonstrate to those
working on these vaccines how Nuvec(R) may enhance subsequent
vaccines they may be looking to develop for this Coronavirus or
other viruses that may well surface in the future."
Enquiries:
N4 Pharma Plc Via Scott PR
Nigel Theobald, CEO
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR
Georgia Smith Tel: +44(0)1477 539 539
Glossary
Peripheral blood mononuclear cells (PBMC) are widely used in
research and toxicology applications. They give selective responses
to the immune system and are the major cells in the human body
immunity. They contain several types of cells such as lymphocytes,
monocytes or macrophages.
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBCGDSSDBDGGU
(END) Dow Jones Newswires
April 16, 2020 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024